Acurx Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
259 Liberty Ave, Staten Island, New York...Phone Number
(917) 533-1469Website
www.acurxpharma.comRevenue
-Stock Symbol
ACXPIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
2
1
1
1
About Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel antibiotics to treat difficult bacterial infections. Its pipeline targets Gram-positive pathogens using a unique DNA polymerase IIIC inhibition approach, with lead candidate ibezapolstat in clinical trials for C. difficile infections, alongside other early-stage antibiotic programs.Explore more
Acurx Pharmaceuticals Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Acurx Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Acurx Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Acurx Pharmaceuticals recently announced quarterly report
Click to see if Acurx Pharmaceuticals had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Acurx Pharmaceuticals has new funding data
Congratulate Masked Content for being promoted to Masked Content at Acurx Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Acurx Pharmaceuticals launches new products
Check out if Acurx Pharmaceuticals is spiking on competitors!
Acurx Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Acurx Pharmaceuticals
Find more new buyers
Compare Similar Companies to Acurx Pharmaceuticals
Compare insights from companies similar to Acurx Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Acurx Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Acurx Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Acurx Pharmaceuticals.
Acurx Pharmaceuticals Tech Stack
A closer look at the technologies used by Acurx Pharmaceuticals
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Product Development, Product Management, Medical Research, Pharmaceuticals, Clinical Operations
Project
Product Development, Product Management, Medical Research, Pharmaceuticals, Clinical Operations
Earnings
Earnings
Earnings
Earnings
Acurx Pharmaceuticals News & Media
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
STATEN ISLAND, N.Y., July 8, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss...Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
Results are from Acurx's ongoing scientific collaboration with Leiden University Medical Center (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitors LUMC highlighted Acurx's new class of promising antimicrobials,...Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
STATEN ISLAND, N.Y., May 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and...Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
DNA pol IIIC inhibitors demonstrate the unexpected benefit of gut microbiome preservation while demonstrating systemic antibacterial activity Neutropenic CD-1 mice were infected intramuscularly with methicillin-resistant Staphylococcus aureus (MRSA) and subsequently treated with one of...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Acurx Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel antibiotics to treat difficult bacterial infections. Its pipeline targets Gram-positive pathogens using a unique DNA polymerase IIIC inhibition approach, with lead candidate ibezapolstat in clinical trials for C. difficile infections, alongside oth... Read More
